Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Advanced Breast Cancer × Safety × Clear all

Status

Active not recruiting 1

Sponsor Class

Study Type

Observational 1

Sponsor

Cancer Type

Conditions

Leukemia, Myeloid, Acute 1 Advanced Breast Cancer 1

Interventions

Fulvestrant 5 olaparib 4 Letrozole 4 Aromatase Inhibitors 3 Anastrozole 3 trastuzumab deruxtecan 2 sacituzumab govitecan 2 pyrotinib 2 dalpiciclib 2 Goserelin 2 FCN-437c 2 Capecitabine 2 talazoparib 1 sonidegib 1 neratinib 1 liposomal doxorubicin 1 eribulin 1 disitamab vedotin 1 ceralasertib 1 capivasertib 1 apatinib 1 abemaciclib 1 Vorinostat 1 Vinorelbine 1 Trastuzumab 1 Tablets 1 Safety 1 Radiotherapy 1 Population Groups 1 N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06926088 2025-04-13

CAMELIA

The First Affiliated Hospital with Nanjing Medical University

Active not recruiting

Advanced Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡